Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care

Jose Luis Górriz; Francesc Xavier Cos Claramunt; Natalia Duque; Arantxa Matali

doi:10.1016/j.pcd.2019.07.001

Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care

Jose Luis Górriz, Francesc Xavier Cos Claramunt, Natalia Duque, Arantxa Matali

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

5 Citations (Scopus)

Abstract

© 2019 Primary Care Diabetes Europe Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.

Original language	English
Pages (from-to)	485-494
Number of pages	10
Journal	Primary Care Diabetes
Volume	13
Issue number	6
DOIs	https://doi.org/10.1016/j.pcd.2019.07.001
Publication status	Published - 1 Dec 2019

Keywords

Diabetic kidney disease
Diabetic nephropathy
Major adverse renal event
Primary care
Renal endpoints
Renal outcome
Type 2 diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pcd.2019.07.001

Cite this

@article{05d285fd9d2147299f72efe826aaffd1,

title = "Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care",

abstract = "{\textcopyright} 2019 Primary Care Diabetes Europe Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.",

keywords = "Diabetic kidney disease, Diabetic nephropathy, Major adverse renal event, Primary care, Renal endpoints, Renal outcome, Type 2 diabetes",

author = "G{\'o}rriz, {Jose Luis} and {Cos Claramunt}, {Francesc Xavier} and Natalia Duque and Arantxa Matali",

year = "2019",

month = dec,

day = "1",

doi = "10.1016/j.pcd.2019.07.001",

language = "English",

volume = "13",

pages = "485--494",

journal = "Primary Care Diabetes",

issn = "1751-9918",

publisher = "Elsevier BV",

number = "6",

}

Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care. / Górriz, Jose Luis; Cos Claramunt, Francesc Xavier; Duque, Natalia et al.

In: Primary Care Diabetes, Vol. 13, No. 6, 01.12.2019, p. 485-494.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care

AU - Górriz, Jose Luis

AU - Cos Claramunt, Francesc Xavier

AU - Duque, Natalia

AU - Matali, Arantxa

PY - 2019/12/1

Y1 - 2019/12/1

N2 - © 2019 Primary Care Diabetes Europe Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.

AB - © 2019 Primary Care Diabetes Europe Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.

KW - Diabetic kidney disease

KW - Diabetic nephropathy

KW - Major adverse renal event

KW - Primary care

KW - Renal endpoints

KW - Renal outcome

KW - Type 2 diabetes

UR - http://www.mendeley.com/research/review-renal-endpoints-used-cardiovascular-safety-clinical-trials-type-2-diabetes-mellitus-patients

U2 - 10.1016/j.pcd.2019.07.001

DO - 10.1016/j.pcd.2019.07.001

M3 - Article

C2 - 31400992

SN - 1751-9918

VL - 13

SP - 485

EP - 494

JO - Primary Care Diabetes

JF - Primary Care Diabetes

IS - 6

ER -

Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this